Carnegie acted as sole global co-ordinator and sole bookrunner in the directed new share issue of approx. 3.9 million shares at a subscription price of GBP 190 pence (EUR 2.198) per share. Faron (LONDON AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response, in oncology and organ damage. Faron is based in Turku, Finland. November 2019.
Healthcare
Directed new share issue in Faron Pharmaceuticals Oy (FI) — EUR 8.7 million
November 2019